Site Search
Displaying results 41 - 50 of 64
Resource | Publications,
Pre-Exposure Prophylaxis (PrEP), “the daily use of antiretrovirals in HIV-uninfected people to block the acquisition of HIV infection,” is a new tool for preventing HIV transmission and has sparked considerable discussion and debate in many communities.
From the International Network of People who Use Drugs, this report summarizes recent research on the knowledge, beliefs, and opinions of people who inject drugs about the pros, cons, and concerns of PrEP for people who inject drugs.
Resource | Publications,
Pre-exposure prophylaxis (PrEP) – the use of HIV antiretroviral (ARV) treatment by HIV-negative individuals to reduce their risk of acquiring HIV - is now recognised as an emerging and fundamental biomedical component of combination HIV prevention approaches.
With 39% of men who have sex with men (MSM) in this study classified as willing to use PrEP and high rates of recent HIV testing, PrEP may be a viable addition to comprehensive HIV prevention strategies for MSM in Myanmar. The recent decentralisation of Myanmar’s health system has seen HIV testing and other services increasingly offered through NGOs and recent investments in the implementation and maintenance of accessible HIV services for MSM may offer an important foundation for PrEP programmes. Demonstration or implementation projects that examine the effectiveness of PrEP in a real life setting, including identification of issues related to drug adherence and logistics associated with PrEP dispensing and monitoring, will be an important next step to guide any future implementation of PrEP in Myanmar.
Resource | Publications,
This report presents the potential for HIV self-testing to contribute to achieving global 90–90–90 targets for treatment access by 2020, provides projections of the demand for and supply of HIV rapid diagnostic tests (RDTs) for self-testing and summarizes the emerging market landscape for self-testing. This information will likely be useful for manufacturers, donors, national programmes, researchers and many other global health stakeholders who are exploring the potential role of HIV self-testing.
Resource | Fact Sheets,
HIV self-testing (HIVST) provides an opportunity for people to test themselves discreetly and conveniently, but it does not provide an HIV diagnosis. Several countries have already introduced or are considering the introduction of HIVST but there are question as to how accurate rapid diagnostic tests (RDTs) adapted for self-testing will be, particularly in the hands of untrained users. This review compiles existing evidence and reports on the accuracy of HIV RDTs used for self-testing.
Resource | Tools,
Implementing PrEP poses new challenges in planning, managing and funding combination prevention. Realizing the promise of PrEP will require governments, funders, civil society and other stakeholders to join forces to systematically address them–licensing antiretroviral medicines for PrEP use, setting priorities for locations and populations for implementation, making services user-friendly and ensuring adherence. These efforts are worthwhile based on their contribution to achieving the global targets of less than 500 000 people annually acquiring HIV in 2020 and the end of AIDS as a public health threat by 2030.
Resource | Fact Sheets,
Oral PrEP containing tenofovir disoproxil fumarate (TDF) should be offered as an additional prevention choice for people at substantial risk of HIV infection as part of combination HIV prevention approaches.
In 2014 WHO recommended offering PrEP to men who have sex with men. On the basis of further evidence of the effectiveness and acceptability of PrEP, WHO has now broadened the recommendation to include all population groups at substantial risk of HIV infection.
Offering PrEP should be a priority for populations with an HIV incidence of about 3 per 100 person-years or higher. PrEP should be an additional prevention choice in a comprehensive package of services that also includes HIV testing, counselling, male and female condoms, lubricants, ARV treatment for partners with HIV infection, voluntary medical male circumcision and harm reduction interventions for people who use drugs.
Resource | Presentations,
PrEPARING ASIA: A New Direction for HIV Prevention among MSM in Asia
Regional Consultation
September 2015
Bangkok
Resource | Presentations,
PrEPARING ASIA: A New Direction for HIV Prevention among MSM in Asia
Regional Consultation
September 2015
Bangkok
Resource | Presentations,
PrEPARING ASIA: A New Direction for HIV Prevention among MSM in Asia
Regional Consultation
September 2015
Bangkok